Altogether, our collective works suggest multiple potential IL6 sources within the TME that could jointly augment GP130-mediated MDM2 transcriptional upregulation – as well as other pro-cancer mechanisms driven by GP130 signaling independent of increasing MDM2 expression – consequently enhancing DDLPS pathogenicity. The gene discussed is IL6; the disease is cancer.